Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mitigation of Defect Formation at the NiO<sub><i>x</i></sub>/Perovskite Interface in p-i-n Perovskite Solar Cells.

ACS applied materials & interfaces·2025

Same author

Co-Doping Approach for Enhanced Electron Extraction to TiO<sub>2</sub> for Stable Inorganic Perovskite Solar Cells.

Small science·2025

Same author

Impacts of traumatic brain injury severity and sex on sleep architecture, duration, and fragmentation.

Neurobiology of sleep and circadian rhythms·2025

Same author

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Retraction Notice to: ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

Electrochemical and Spectro-Microscopic Analyses of Charge Accumulation and Ion Migration in Dry Processed Perovskite Solar Cells under Electrical Biasing.

The journal of physical chemistry letters·2025

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time

Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time

Published on: May 30, 2021

Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Sharareh Emadi¹, Srinath Kasturirangan, Min S Wang

¹Department of Chemical Engineering, Arizona State University, Tempe, Arizona 85287-6006, USA.

The Journal of Biological Chemistry

|January 15, 2009

Summary

Researchers developed a novel antibody fragment that targets toxic alpha-synuclein aggregates. This discovery offers potential diagnostic and therapeutic strategies for Parkinson disease (PD) by specifically recognizing pathological forms in brain tissue.

More Related Videos

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

Related Experiment Videos

Last Updated: Jun 26, 2026

Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time

Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time

Published on: May 30, 2021

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

Area of Science:

Neuroscience
Biochemistry
Immunology

Background:

Misfolding and aggregation of alpha-synuclein are strongly linked to Parkinson disease (PD) pathogenesis.
Oligomeric forms of alpha-synuclein are implicated as toxic species causing neurodegeneration.
The specific toxic oligomeric forms involved in PD and their roles remain unclear.

Purpose of the Study:

To identify and characterize novel reagents that specifically interact with toxic alpha-synuclein aggregates.
To develop tools for studying the role of different alpha-synuclein aggregate forms in PD.
To explore potential diagnostic and therapeutic agents for PD targeting alpha-synuclein.

Main Methods:

Isolation of a single chain antibody fragment (syn-10H scFv) using phage display.
Characterization of the binding specificity of syn-10H scFv to various alpha-synuclein oligomeric forms.
In vitro aggregation inhibition assays.
Assessment of syn-10H scFv's ability to block alpha-synuclein-induced toxicity in human neuroblastoma cell lines (SH-SY5Y).
Immunohistochemical analysis of PD and healthy human brain tissue.

Main Results:

A novel scFv (syn-10H scFv) was identified that binds to larger, later-stage alpha-synuclein oligomers.
Syn-10H scFv inhibits alpha-synuclein aggregation in vitro.
The antibody fragment blocks extracellular alpha-synuclein toxicity in SH-SY5Y cells.
Syn-10H scFv specifically recognizes naturally occurring alpha-synuclein aggregates in PD brain tissue, but not in healthy brain tissue.

Conclusions:

Syn-10H scFv is a potent inhibitor of alpha-synuclein aggregation and toxicity.
This antibody fragment specifically targets pathological alpha-synuclein aggregates found in Parkinson disease.
Syn-10H scFv represents a promising tool for PD research and a potential diagnostic and therapeutic candidate.